Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes

Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims: The increased risk of fractures in patients with type 2 diabetes can partly be explained by poor bone quality and extra-skeletal factors. A retrospective study was conducted to compare the outcome of alendronate (ALN) treatment for 3 years in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Methods: One-hundred and fifty-one postmenopausal osteoporotic Japanese women (mean age at baseline: 67.8 years) who had been treated with ALN for more than 3 years in our outpatient clinic were analysed. The lumbar spine bone mineral density (BMD) was measured using dual energy X-ray absorptiometry, and the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and the serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Sixteen women had type 2 diabetes and were receiving pharmacological treatment, and 135 were non-diabetic. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, without causing any severe adverse events including osteonecrosis of the jaw, femoral diaphysis atypical fractures, and atrial fibrillation, in a manner that was similar among women with type 2 diabetes and non-diabetics. However, the incidence of non-vertebral fractures was significantly higher among women with type 2 diabetes than among the non-diabetics. Conclusions: ALN treatment appeared to have the similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Because of lacking in statistical power for fracture incidence due to the small sample size, further studies are warranted to confirm the results of the fracture incidence.

Original languageEnglish
Pages (from-to)166-173
Number of pages8
JournalDiabetes Research and Clinical Practice
Volume93
Issue number2
DOIs
Publication statusPublished - 2011 Aug

Fingerprint

Alendronate
Type 2 Diabetes Mellitus
Incidence
Bone Density
Alkaline Phosphatase
Spine
Therapeutics
Diaphyses
Osteoporotic Fractures
Osteonecrosis
Photon Absorptiometry
Thigh
Ambulatory Care Facilities
Jaw
Serum
Sample Size
Atrial Fibrillation
Retrospective Studies
Biomarkers
Pharmacology

Keywords

  • Alendronate
  • Bone mineral density
  • Bone turnover
  • Osteoporosis
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Cite this

Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. / Iwamoto, Jun; Sato, Yoshihiro; Uzawa, Mitsuyoshi; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Diabetes Research and Clinical Practice, Vol. 93, No. 2, 08.2011, p. 166-173.

Research output: Contribution to journalArticle

Iwamoto, Jun ; Sato, Yoshihiro ; Uzawa, Mitsuyoshi ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. In: Diabetes Research and Clinical Practice. 2011 ; Vol. 93, No. 2. pp. 166-173.
@article{703dc8e854fb4a24a2e846293e40de1f,
title = "Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes",
abstract = "Aims: The increased risk of fractures in patients with type 2 diabetes can partly be explained by poor bone quality and extra-skeletal factors. A retrospective study was conducted to compare the outcome of alendronate (ALN) treatment for 3 years in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Methods: One-hundred and fifty-one postmenopausal osteoporotic Japanese women (mean age at baseline: 67.8 years) who had been treated with ALN for more than 3 years in our outpatient clinic were analysed. The lumbar spine bone mineral density (BMD) was measured using dual energy X-ray absorptiometry, and the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and the serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Sixteen women had type 2 diabetes and were receiving pharmacological treatment, and 135 were non-diabetic. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, without causing any severe adverse events including osteonecrosis of the jaw, femoral diaphysis atypical fractures, and atrial fibrillation, in a manner that was similar among women with type 2 diabetes and non-diabetics. However, the incidence of non-vertebral fractures was significantly higher among women with type 2 diabetes than among the non-diabetics. Conclusions: ALN treatment appeared to have the similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Because of lacking in statistical power for fracture incidence due to the small sample size, further studies are warranted to confirm the results of the fracture incidence.",
keywords = "Alendronate, Bone mineral density, Bone turnover, Osteoporosis, Type 2 diabetes",
author = "Jun Iwamoto and Yoshihiro Sato and Mitsuyoshi Uzawa and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2011",
month = "8",
doi = "10.1016/j.diabres.2011.03.033",
language = "English",
volume = "93",
pages = "166--173",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes

AU - Iwamoto, Jun

AU - Sato, Yoshihiro

AU - Uzawa, Mitsuyoshi

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2011/8

Y1 - 2011/8

N2 - Aims: The increased risk of fractures in patients with type 2 diabetes can partly be explained by poor bone quality and extra-skeletal factors. A retrospective study was conducted to compare the outcome of alendronate (ALN) treatment for 3 years in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Methods: One-hundred and fifty-one postmenopausal osteoporotic Japanese women (mean age at baseline: 67.8 years) who had been treated with ALN for more than 3 years in our outpatient clinic were analysed. The lumbar spine bone mineral density (BMD) was measured using dual energy X-ray absorptiometry, and the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and the serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Sixteen women had type 2 diabetes and were receiving pharmacological treatment, and 135 were non-diabetic. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, without causing any severe adverse events including osteonecrosis of the jaw, femoral diaphysis atypical fractures, and atrial fibrillation, in a manner that was similar among women with type 2 diabetes and non-diabetics. However, the incidence of non-vertebral fractures was significantly higher among women with type 2 diabetes than among the non-diabetics. Conclusions: ALN treatment appeared to have the similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Because of lacking in statistical power for fracture incidence due to the small sample size, further studies are warranted to confirm the results of the fracture incidence.

AB - Aims: The increased risk of fractures in patients with type 2 diabetes can partly be explained by poor bone quality and extra-skeletal factors. A retrospective study was conducted to compare the outcome of alendronate (ALN) treatment for 3 years in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Methods: One-hundred and fifty-one postmenopausal osteoporotic Japanese women (mean age at baseline: 67.8 years) who had been treated with ALN for more than 3 years in our outpatient clinic were analysed. The lumbar spine bone mineral density (BMD) was measured using dual energy X-ray absorptiometry, and the urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and the serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Sixteen women had type 2 diabetes and were receiving pharmacological treatment, and 135 were non-diabetic. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, without causing any severe adverse events including osteonecrosis of the jaw, femoral diaphysis atypical fractures, and atrial fibrillation, in a manner that was similar among women with type 2 diabetes and non-diabetics. However, the incidence of non-vertebral fractures was significantly higher among women with type 2 diabetes than among the non-diabetics. Conclusions: ALN treatment appeared to have the similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Because of lacking in statistical power for fracture incidence due to the small sample size, further studies are warranted to confirm the results of the fracture incidence.

KW - Alendronate

KW - Bone mineral density

KW - Bone turnover

KW - Osteoporosis

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=80051572682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051572682&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2011.03.033

DO - 10.1016/j.diabres.2011.03.033

M3 - Article

VL - 93

SP - 166

EP - 173

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -